A Study of Actonel for the Prevention of Bone Loss
Status:
Completed
Trial end date:
2014-08-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn if Actonel (risedronate) can help to
prevent the development of osteoporosis (brittle and weak bones) caused by the steroid
medication used to treat leukemia. The safety of this treatment in patients with ALL or LL
will also be studied.